Susceptibility of Anopheles gambiae from Côte d'Ivoire to insecticides used on insecticide-treated nets: evaluating the additional entomological impact of piperonyl butoxide and chlorfenapyr.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
09 Dec 2020
Historique:
received: 02 04 2020
accepted: 25 11 2020
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 3 9 2021
Statut: epublish

Résumé

Pyrethroid-treated mosquito nets are currently the mainstay of vector control in Côte d'Ivoire. However, resistance to pyrethroids has been reported across the country, limiting options for insecticide resistance management due to the paucity of alternative insecticides. Two types of insecticide-treated nets (ITNs), ITNs with pyrethroids and the synergist piperonyl butoxide (PBO), and Interceptor®G2 nets, a net treated with a combination of chlorfenapyr and alpha-cypermethrin, are believed to help in the control of pyrethroid-resistant mosquitoes. The susceptibility of Anopheles gambiae sensu lato (s.l.) to pyrethroid insecticides with and without pre-exposure to PBO as well as to chlorfenapyr was investigated in fifteen sites across the country. Susceptibility tests were conducted on 2- to 4-day old adult female An. gambiae s.l. reared from larval collections. The resistance status, intensity, and effects of PBO on mortality after exposure to different concentrations of deltamethrin, permethrin and alpha-cypermethrin were determined using WHO susceptibility test kits. In the absence of a WHO-recommended standard protocol for chlorfenapyr, two interim doses (100 and 200 µg/bottle) were used to test the susceptibility of mosquitoes using the CDC bottle assay method. Pre-exposure to PBO did not result in full restoration of susceptibility to any of the three pyrethroids for the An. gambiae s.l. populations from any of the sites surveyed. However, PBO pre-exposure did increase mortality for all three pyrethroids, particularly deltamethrin (from 4.4 to 48.9%). Anopheles gambiae s.l. from only one site (Bettie) were susceptible to chlorfenapyr at the dose of 100 µg active ingredient (a.i.)/bottle. At the dose of 200 µg (a.i.)/bottle, susceptibility was only recorded in 10 of the 15 sites. Low mosquito mortality was found for pyrethroids alone, and while PBO increased mortality, it did not restore full susceptibility. The vector was not fully susceptible to chlorfenapyr in one third of the sites tested. However, vector susceptibility to chlorfenapyr seems to be considerably higher than for pyrethroids alone or with PBO. These data should be used cautiously when making ITN procurement decisions, noting that bioassays are conducted in controlled conditions and may not fully represent field efficacy where the host-seeking behaviours, which include free-flying activity are known to enhance pro-insecticide chlorfenapyr intoxication to mosquitoes.

Sections du résumé

BACKGROUND BACKGROUND
Pyrethroid-treated mosquito nets are currently the mainstay of vector control in Côte d'Ivoire. However, resistance to pyrethroids has been reported across the country, limiting options for insecticide resistance management due to the paucity of alternative insecticides. Two types of insecticide-treated nets (ITNs), ITNs with pyrethroids and the synergist piperonyl butoxide (PBO), and Interceptor®G2 nets, a net treated with a combination of chlorfenapyr and alpha-cypermethrin, are believed to help in the control of pyrethroid-resistant mosquitoes.
METHODS METHODS
The susceptibility of Anopheles gambiae sensu lato (s.l.) to pyrethroid insecticides with and without pre-exposure to PBO as well as to chlorfenapyr was investigated in fifteen sites across the country. Susceptibility tests were conducted on 2- to 4-day old adult female An. gambiae s.l. reared from larval collections. The resistance status, intensity, and effects of PBO on mortality after exposure to different concentrations of deltamethrin, permethrin and alpha-cypermethrin were determined using WHO susceptibility test kits. In the absence of a WHO-recommended standard protocol for chlorfenapyr, two interim doses (100 and 200 µg/bottle) were used to test the susceptibility of mosquitoes using the CDC bottle assay method.
RESULTS RESULTS
Pre-exposure to PBO did not result in full restoration of susceptibility to any of the three pyrethroids for the An. gambiae s.l. populations from any of the sites surveyed. However, PBO pre-exposure did increase mortality for all three pyrethroids, particularly deltamethrin (from 4.4 to 48.9%). Anopheles gambiae s.l. from only one site (Bettie) were susceptible to chlorfenapyr at the dose of 100 µg active ingredient (a.i.)/bottle. At the dose of 200 µg (a.i.)/bottle, susceptibility was only recorded in 10 of the 15 sites.
CONCLUSION CONCLUSIONS
Low mosquito mortality was found for pyrethroids alone, and while PBO increased mortality, it did not restore full susceptibility. The vector was not fully susceptible to chlorfenapyr in one third of the sites tested. However, vector susceptibility to chlorfenapyr seems to be considerably higher than for pyrethroids alone or with PBO. These data should be used cautiously when making ITN procurement decisions, noting that bioassays are conducted in controlled conditions and may not fully represent field efficacy where the host-seeking behaviours, which include free-flying activity are known to enhance pro-insecticide chlorfenapyr intoxication to mosquitoes.

Identifiants

pubmed: 33298071
doi: 10.1186/s12936-020-03523-y
pii: 10.1186/s12936-020-03523-y
pmc: PMC7725118
doi:

Substances chimiques

Insecticides 0
Pesticide Synergists 0
Pyrethrins 0
Piperonyl Butoxide LWK91TU9AH
chlorfenapyr NWI20P05EB

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

454

Subventions

Organisme : USAID/PMI
ID : AID-OAA-I-17-00008

Références

Med Vet Entomol. 1989 Jul;3(3):263-71
pubmed: 2519671
Malar J. 2016 Aug 24;15(1):426
pubmed: 27553959
Trop Med Int Health. 2010 Jan;15(1):127-31
pubmed: 19891759
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Malar J. 2017 May 8;16(1):190
pubmed: 28482891
Trop Med Int Health. 2009 Apr;14(4):389-95
pubmed: 19228349
Trends Parasitol. 2011 Feb;27(2):91-8
pubmed: 20843745
Infect Dis Poverty. 2019 Jul 15;8(1):64
pubmed: 31307509
Malar J. 2010 Apr 27;9:113
pubmed: 20423479
Ann Trop Med Parasitol. 2008 Jun;102(4):367-76
pubmed: 18510817
Med Vet Entomol. 2003 Mar;17(1):19-25
pubmed: 12680920
Acta Trop. 2011 Apr;118(1):50-5
pubmed: 21315680
Parasit Vectors. 2014 Nov 28;7:500
pubmed: 25429888
Malar J. 2017 Aug 17;16(1):342
pubmed: 28818077
Malar J. 2019 Feb 22;18(1):49
pubmed: 30795768
Malar J. 2011 Nov 16;10:343
pubmed: 22087506
Malar J. 2011 Jan 25;10:16
pubmed: 21266037
Malar J. 2015 Mar 24;14:124
pubmed: 25879231
J Insect Physiol. 2014 May;64:30-9
pubmed: 24631684
PLoS One. 2016 Nov 16;11(11):e0165925
pubmed: 27851828
Parasit Vectors. 2018 Jan 8;11(1):19
pubmed: 29310704
Trends Parasitol. 2016 Mar;32(3):187-196
pubmed: 26826784
Parassitologia. 1999 Sep;41(1-3):319-22
pubmed: 10697876
PLoS One. 2014 Feb 03;9(2):e87710
pubmed: 24498360
Med Vet Entomol. 2000 Mar;14(1):1-5
pubmed: 10759305
Emerg Infect Dis. 2012 Sep;18(9):1508-11
pubmed: 22932478
Malar J. 2007 Aug 13;6:111
pubmed: 17697325
PLoS Biol. 2009 Apr 7;7(4):e1000058
pubmed: 19355786
Bull Soc Pathol Exot. 2017 May;110(2):130-134
pubmed: 28357641
J Am Mosq Control Assoc. 1999 Mar;15(1):53-9
pubmed: 10342269
J Med Entomol. 2006 Jan;43(1):55-60
pubmed: 16506447
Parasite. 2018;25:42
pubmed: 30088473
PLoS One. 2018 Jul 11;13(7):e0192492
pubmed: 29995894
Malar J. 2019 Jul 17;18(1):243
pubmed: 31315614
Insect Mol Biol. 2004 Feb;13(1):1-7
pubmed: 14728661
Insect Mol Biol. 2000 Oct;9(5):499-507
pubmed: 11029668
Malar J. 2008 Aug 25;7:163
pubmed: 18724871
Biomed Res Int. 2018 Oct 8;2018:2874160
pubmed: 30402467

Auteurs

Bernard L Kouassi (BL)

PMI VectorLink project, Abidjan, Côte d'Ivoire.

Constant Edi (C)

Swiss Center of Scientific Research in Côte d'Ivoire, Abidjan, Côte d'Ivoire.

Emmanuel Tia (E)

Centre of Veterinary and Medical Entomology, Abidjan, Côte d'Ivoire.

Lucien Y Konan (LY)

National Institute of Public Hygiene, Abidjan, Côte d'Ivoire.

Maurice A Akré (MA)

National Institute of Public Health/Pierre Richet Institute, Bouake, Côte d'Ivoire.

Alphonsine A Koffi (AA)

National Institute of Public Health/Pierre Richet Institute, Bouake, Côte d'Ivoire.

Allassane F Ouattara (AF)

Swiss Center of Scientific Research in Côte d'Ivoire, Abidjan, Côte d'Ivoire.

Antoine Mea Tanoh (AM)

National Malaria Control Programme, Abidjan, Côte d'Ivoire.

Pascal Zinzindohoue (P)

U.S. President's Malaria Initiative, USAID, Abidjan, Côte d'Ivoire.

Blaise Kouadio (B)

U.S. President's Malaria Initiative, USAID, Abidjan, Côte d'Ivoire.

McKenzie Andre (M)

National Malaria Control Programme, Abidjan, Côte d'Ivoire.

Seth R Irish (SR)

U.S. President's Malaria Initiative, Entomology Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.

Jennifer Armistead (J)

U.S. President's Malaria Initiative, USAID, Washington, DC, USA.

Dereje Dengela (D)

PMI VectorLink Project, Washington, DC, USA.

Ndombour G Cissé (NG)

PMI VectorLink project, Abidjan, Côte d'Ivoire.

Cecilia Flatley (C)

PMI VectorLink Project, Washington, DC, USA.

Joseph Chabi (J)

PMI VectorLink project, Abidjan, Côte d'Ivoire. Joseph_Chabi@pmivectorlink.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH